Northwest Biotherapeutics Inc NWBO

Healthcare Biotechnology

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

OTCQB:NWBO - Post by User

Northwest Biotherapeutics Inc

Bullboard Posts

Post by pericles1on Feb 21, 2014 9:07am

178 Views

Post# 22233871

Waiting

Waiting for the news, I am amused by the Yahoo board when the stock goes up strongly it's wildly optimistic and when it's down the bashers come out. I do not expect the stock to go over 7 unless we get a early stop recommendation on the trial which I do not expect. IMUC has taught me to curb my expectations. No Direct results until ASCO so we have a few months to wait for that one. Have my fingers crossed good luck everyone!

Bullboard Posts

Understanding tax loss season and the “Santa Claus rally”